Evidence map›Paper›PMID 24421266›Full record

Trial reportJournal of leukocyte biology2014

Oral delivery of oligomeric procyanidins in Apple Poly® enhances type I IFN responses in vivo.

Deann T Snyder, Amanda Robison, Sharon Kemoli, Emily Kimmel, Jeff Holderness, Mark A Jutila, Jodi F Hedges

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Journal of leukocyte biology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Deann T SnyderDepartment of Immunology and Infectious Diseases, Montana State University, Bozeman, Montana, USA.
Amanda RobisonDepartment of Immunology and Infectious Diseases, Montana State University, Bozeman, Montana, USA.
Sharon KemoliDepartment of Immunology and Infectious Diseases, Montana State University, Bozeman, Montana, USA.
Emily KimmelDepartment of Immunology and Infectious Diseases, Montana State University, Bozeman, Montana, USA.
Jeff HoldernessDepartment of Immunology and Infectious Diseases, Montana State University, Bozeman, Montana, USA.
Mark A JutilaDepartment of Immunology and Infectious Diseases, Montana State University, Bozeman, Montana, USA.
Jodi F HedgesDepartment of Immunology and Infectious Diseases, Montana State University, Bozeman, Montana, USA jodi.hedges@gmail.com.

Funding

VIRUSES: FROM PARTICLES TO PROTEOMICSP20RR020185 · NCRR · MONTANA STATE UNIVERSITY - BOZEMAN · PI QUINN, MARK T · 2004 to 2011
$17.0M
CAMs as counter measures against infectious and inflammatory diseaseP01AT004986 · NCCIH · MONTANA STATE UNIVERSITY - BOZEMAN · PI JUTILA, MARK A · 2008 to 2012
$5.9M
Center for Zoonotic and Emerging Infectious DiseasesP20GM103500 · NIGMS · MONTANA STATE UNIVERSITY - BOZEMAN · PI QUINN, MARK T · 2012 to 2013
$4.2M
NCCIH NIH HHS P01 AT004986NCRR NIH HHS P20 RR020185NIGMS NIH HHS P20 GM103500
6 · The paper itself

Abstract

Type I IFN signaling is a central pathway that provides critical innate protection from viral and bacterial infection and can have regulatory outcomes in inflammatory settings. We determined previously that OPCs contained in the dietary supplement APP enhanced responses to type I IFN in vitro. Here, we confirm that OPCs from two different sources significantly increased pSTAT1, whereas a monomeric form of procyanidin did not. We hypothesized that similar responses could be induced in vivo following ingestion of APP. Ingestion of APP before injection of polyI:C enhanced in vivo responses to type I IFNs in mice. When human subjects ingested APP, enhanced responses to type I IFN and enhanced pSTAT1 ex vivo were detected, whereas ingestion of RES, a monomeric polyphenol, induced minimal such changes. Polyphenols are best known for induction of anti-inflammatory and antioxidant responses; however, our findings suggest a unique, nonantioxidant aspect of OPCs that is broadly applicable to many disease settings. The capacity of oral OPCs to enhance type I IFN signaling in vivo can augment innate protection and may, in part, contribute to the noted anti-inflammatory outcome of ingestion of OPCs from many sources.

Indexed as

Administration, OralAnimalsBiflavonoidsCatechinChlorogenic AcidDouble-Blind MethodFemaleFlavonoidsHumansImmunity, InnateInterferon Type IMaleMiceMice, Inbred BALB CProanthocyanidinsTanninsapple polyphenol extractBiflavonoidsCatechinChlorogenic AcidFlavonoidsInterferon Type IProanthocyanidinsprocyanidinTanninsautoimmunecomplementary therapyinnate antiviral

Identifiers

PMID24421266
PMCPMC3984970

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.